SPRINGWORKS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.38 USD | -1.41% |
|
-1.65% | +18.85% |
Presenter SpeechCorinne Jenkins (Analysts)Good afternoon, everyone. We are excited to welcome ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
43.38
USD
Average target price
67.28
USD
Spread / Average Target
+55.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.85% | 3.2B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.69% | 22.2B | |
| -16.53% | 21.23B | |
| -9.10% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- SWTX Stock
- News SpringWorks Therapeutics, Inc.
- Transcript : SpringWorks Therapeutics, Inc. Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-08-2021 03
